190 related articles for article (PubMed ID: 10372512)
1. Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment.
ThyagaRajan S; Stevens SY; Felten DL
Brain Res Bull; 1999 Mar; 48(5):513-20. PubMed ID: 10372512
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.
ThyagaRajan S; Quadri SK
Endocrine; 1999 Jun; 10(3):225-32. PubMed ID: 10484286
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors.
ThyagaRajan S; Felten SY; Felten DL
Cancer Lett; 1998 Jan; 123(2):177-83. PubMed ID: 9489486
[TBL] [Abstract][Full Text] [Related]
4. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
Sivam SP
Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
6. L-Deprenyl stimulates the release of catecholamines in the rat medial basal hypothalamus in vivo.
ThyagaRajan S; Quadri SK
Neurosci Lett; 1999 Jul; 270(2):79-82. PubMed ID: 10462102
[TBL] [Abstract][Full Text] [Related]
7. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.
Thyagarajan S; Meites J; Quadri SK
Endocrinology; 1995 Mar; 136(3):1103-10. PubMed ID: 7867565
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
9. Restoration of sympathetic noradrenergic nerve fibers in the spleen by low doses of L-deprenyl treatment in young sympathectomized and old Fischer 344 rats.
ThyagaRajan S; Felten SY; Felten DL
J Neuroimmunol; 1998 Jan; 81(1-2):144-57. PubMed ID: 9521616
[TBL] [Abstract][Full Text] [Related]
10. Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro.
MohanKumar PS; MohanKumar SM; Quadri SK
Brain Res Bull; 2001 Apr; 54(6):675-80. PubMed ID: 11403995
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
12. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
Tekes K; Tóthfalusi L; Gaál J; Magyar K
Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
[TBL] [Abstract][Full Text] [Related]
13. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
Kato T; Dong B; Ishii K; Kinemuchi H
J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
[TBL] [Abstract][Full Text] [Related]
14. Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation.
Ingram DK; Wiener HL; Chachich ME; Long JM; Hengemihle J; Gupta M
Neurobiol Aging; 1993; 14(5):431-40. PubMed ID: 8247225
[TBL] [Abstract][Full Text] [Related]
15. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.
Lakshmana MK; Rao BS; Dhingra NK; Ravikumar R; Govindaiah ; Sudha S; Meti BL; Raju TR
Neurochem Res; 1998 Aug; 23(8):1031-7. PubMed ID: 9704592
[TBL] [Abstract][Full Text] [Related]
16. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
17. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
18. Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.
Gupta M; Wiener HL
Neurochem Res; 1995 Apr; 20(4):385-9. PubMed ID: 7544444
[TBL] [Abstract][Full Text] [Related]
19. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
Knoll J
J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
[TBL] [Abstract][Full Text] [Related]
20. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
